Trium Capital LLP Boosts Position in Quanterix Corporation $QTRX

Trium Capital LLP increased its position in shares of Quanterix Corporation (NASDAQ:QTRX) by 17.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 688,597 shares of the company’s stock after acquiring an additional 102,172 shares during the quarter. Quanterix makes up about 1.5% of Trium Capital LLP’s portfolio, making the stock its 12th biggest holding. Trium Capital LLP’s holdings in Quanterix were worth $3,739,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. State of Wyoming purchased a new position in Quanterix during the first quarter worth about $47,000. Quantbot Technologies LP increased its holdings in shares of Quanterix by 245.9% during the 1st quarter. Quantbot Technologies LP now owns 11,272 shares of the company’s stock worth $73,000 after buying an additional 8,013 shares during the last quarter. HUB Investment Partners LLC acquired a new stake in shares of Quanterix during the 2nd quarter worth approximately $81,000. Brevan Howard Capital Management LP purchased a new stake in shares of Quanterix during the 2nd quarter valued at approximately $96,000. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in Quanterix by 40.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,024 shares of the company’s stock valued at $100,000 after acquiring an additional 4,330 shares during the last quarter. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Quanterix Stock Down 0.1%

Shares of NASDAQ QTRX opened at $6.64 on Friday. The business’s 50 day moving average is $6.32 and its two-hundred day moving average is $5.82. Quanterix Corporation has a 52-week low of $4.05 and a 52-week high of $12.41. The firm has a market cap of $309.92 million, a price-to-earnings ratio of -2.85 and a beta of 1.01.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.13). Quanterix had a negative return on equity of 21.34% and a negative net margin of 73.47%.The firm had revenue of $40.23 million for the quarter, compared to analysts’ expectations of $37.85 million. Analysts anticipate that Quanterix Corporation will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quanterix in a research report on Wednesday, October 8th. Canaccord Genuity Group upped their price target on Quanterix from $5.00 to $8.00 and gave the company a “hold” rating in a research note on Monday. Finally, Wall Street Zen downgraded Quanterix from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $11.33.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.